EP2970246A1 - Luciférines à émission décalée vers le rouge et leurs procédés d'utilisation - Google Patents

Luciférines à émission décalée vers le rouge et leurs procédés d'utilisation

Info

Publication number
EP2970246A1
EP2970246A1 EP14714053.7A EP14714053A EP2970246A1 EP 2970246 A1 EP2970246 A1 EP 2970246A1 EP 14714053 A EP14714053 A EP 14714053A EP 2970246 A1 EP2970246 A1 EP 2970246A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
substituted
compound according
luciferase
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14714053.7A
Other languages
German (de)
English (en)
Other versions
EP2970246B1 (fr
Inventor
Woodroofe Carolyn HITKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of EP2970246A1 publication Critical patent/EP2970246A1/fr
Application granted granted Critical
Publication of EP2970246B1 publication Critical patent/EP2970246B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)

Definitions

  • Bioluminescence with a longer-wavelength and lower-energy emission is of significant interest both for multiplexing applications with multiple emission colors and for in-depth tissue imaging where shorter wavelengths tend to be strongly absorbed.
  • Many standard systems for optical imaging have limited utility in a whole-animal context due to the diminished transmission of light through biological samples. Light penetration is limited by the absorption coefficients of particular components in blood. Strong absorption by Hemoglobin (Hb) and oxygenated hemoglobin (HbC ⁇ ) diminish transmission (and penetration depth) of light through blood and animal tissues.
  • Luminescent systems that emit light in the far red and near infrared region (680- 900nm) allow for optimal imaging due to a minimum in absorbance spectrums of Hb and HbC>2.
  • Bioluminescent reporter systems have been used extensively in research animals, yet still suffer from the limitations of diminished tissue penetration. Typical bioluminescent light emission wavelengths (460-620nm) occur in a region with limited penetration depth. The ideal bioluminescent reporter systems in whole animals would benefit greatly from the bright light emission in the region of 680-900nm. While numerous bioluminescent systems have been modified to shift visible light emission toward the red, none has achieved strong emission red enough to overlap significantly with the critical "optical window" of blood transmittance.
  • the invention provides a compound of formula to Formulas (la), (lb) and (Ic):
  • each Y is independently halo, S0 3 H, Ci_ 4 alkyl, substituted Ci_ 4 alkyl, OR 1 or NR X R 2 ; each R 1 is H, C 1-10 alkyl or substituted C 1-10 alkyl;
  • each R 2 is H, C 1-10 alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring
  • n 1 to 6;
  • two Y substituents may join together to form a ring containing from 5 to 7 ring atoms
  • At least one Y is either OH or NR X R 2 .
  • the invention provides a compound according to Formula (II):
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (III)
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (V):
  • Y is OR 1 or NR ! R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (VI):
  • Y is OR 1 or R ! R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (VII):
  • each Y is independently OR 1 or NR X R 2 ;
  • each R 1 is independently H, C 1-10 alkyl or substituted C 1-10 alkyl
  • each R 2 is independently H, C 1-10 alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (IX):
  • Y is OR
  • W is S, NR N , or O ;
  • Z is S, NR N , O or CH;
  • RN is H, Ci-4 alkyl, or substituted C 1-4 alkyl.
  • the invention provides a compound according to Formula (X):
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • the invention provides a compound according to Formula (XI):
  • Y is OR
  • the invention provides a compound according to Formula (XII):
  • R is or A is OR or NHAc
  • each R5 is independently H, a monosaccharide or a polyethylene glycol moiety of up to 40 units.
  • the invention provides a compound according to Formula (XIII):
  • R7 is an amino acid side chain
  • Re is H, a nitrogen protecting group, or a chain of up to 35 amino acids.
  • the invention provides a compound according to Formula (XIV):
  • X is -CH(OR 10 ) 2 ;
  • Rio is Ci-4 alkyl, substituted C 1-4 alkyl, benzyl, or substituted benzyl;
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • the invention provides a compound according to Formula (XV):
  • Y is H or OR
  • R is Ci-io alkyl, substituted C 1-10 alkylaryl, substituted aryl, aralkyl or substituted aralkyl.
  • the invention provides a compound according to Formula (XVI):
  • X is -CH(OR 10 ) 2 ;
  • Rio Ci-4 alkyl, substituted Ci -4 alkyl, benzyl or substituted benzyl;
  • Y is OR 1 or R X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • the invention provides a compound according to Formula (XVII):
  • R 8 is CH 2 OH, C(0)Rio or -C(0)ZR 9 ;
  • Z is O or H
  • Rg is Ci-7 alkyl or substituted C 1-7 alkyl
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • the invention provides a compound according to Formula (XVII
  • Y is OR
  • each Rii is independently H, Ci_6 alkyl, substituted Ci_6 alkyl, CF 3 , halogen, NO2, CO2R12 or any two adjacent Rn can form a fused ring provided that at least one of Rn is O2; and R12 is H, Ci-6 alkyl or substituted Ci_6 alkyl.
  • the invention provides a compound according to Formula (XIX):
  • Y is O, NH, N(Ci_7 alkyl), or N(substituted Ci_ 7 alkyl);
  • Z is absent or O
  • A is Ci-4 alkylene or substituted C1-4 alkylene
  • Ri4 is H, phenacetyl, or a cephalosporin side chain.
  • the invention provides a compound according to Formula (XX):
  • Y is L-R
  • L is a linker
  • R is a boronic acid or borate ester.
  • the invention provides a method for detecting luminescence in a sample comprising contacting a sample with a compound according to the present invention; contacting the sample with a luciferase, if it is not present in the sample; and detecting luminescence.
  • the invention provides A method for detecting luminescence in a transgenic animal comprising administering a compound according to the present invention to a transgenic animal; and detecting luminescence; wherein the transgenic animal expresses a luciferase.
  • the invention provides a method of detecting the presence or amount of a non- luciferase enzyme comprising contacting a sample suspected of containing the enzyme with a compound according to the invention; adding a luciferase reaction mixture to the sample; and detecting luminescence of the sample.
  • the invention provides a method of detecting the presence of a non-luciferase enzyme in vivo comprising administering a compound according to the invention to a transgenic animal and detecting luminescence; wherein the transgenic animal expresses luciferase.
  • the invention provides a method of detecting the presence of a non-luciferase enzyme comprising administering a compound according to the invention to an animal; obtaining a sample from the animal; adding a luciferase reaction mixture to the sample; and detecting luminescence of the sample.
  • the invention provides an in vitro method of screening for modulators of a non-luciferase enzyme comprising contacting cells with a test compound; adding a compound according to any one of claims 22-33 to form a mixture; adding a luciferase reaction mixture to the mixture; and detecting luminescence.
  • the invention provides a kit comprising a compound according to the invention.
  • FIG. 1 illustrates the bioluminescent response of leucine adducts of amino luciferin control (Leu-luciferin; black circles) or aminoisonaphtholuciferin (PBI-5044; gray squares) as a function of added aminopeptidase.
  • FIG. 2 illustrates the Km of leucinyl aminoisonaphtholuciferin with respect to aminopeptidase.
  • FIG. 3 illustrates that a luciferin substrate (which generates green light) and a substrate of the present invention can be multiplexed, i.e., added to the same sample, and luminescence from each detected with little interference from the other.
  • FIG. 4 illustrates use of a luminescent ester pro-substrate, PBI-5045, of the present invention to report esterase activity.
  • FIG. 4A shows the luminescence (RLUs), and
  • FIG. 4B shows the fold luminescence over background.
  • FIG. 5 shows a cytotoxicity profile for PBI-4813 and 4739.
  • FIG. 6 shows data from clinical signs and animal behavior after a single dose of PBI-4739 or PBI-4813 in female CD-I mice.
  • FIG. 7 shows the survival rate after a single dose of PBI-4739 or PBI-4813 in female CD- 1 mice.
  • FIG. 8 shows body weights in grams after a single dose of PBI-4739 or PBI-4813 in female CD- 1 mice.
  • FIG. 9 shows body weights in percentages after a single dose of PBI-4739 or PBI-4813 in female CD- 1 mice.
  • FIG. 10 shows necropsy results after a single dose of PBI-4739 or PBI-4813 in female CD-I mice.
  • FIG. 1 1 shows the chemiluminescent signal of PBI-4379.
  • FIG. 12 shows fluorescent data for PBI-4379.
  • FIG. 13 shows fluorescent data for PBI-4813.
  • FIG. 14 shows the spectral data for PBI-4739 and PBI-4813 demonstrating their near-IR properties.
  • the following terms and expressions have the indicated meanings. It will be appreciated that the compounds of the present invention contain asymmetrically substituted carbon atoms and may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are part of this invention.
  • substituted is intended to indicate that one or more (e.g., 1, 2, 3, 4, or 5; in some embodiments 1, 2, or 3; and in other embodiments 1 or 2) hydrogens on the group indicated in the expression using "substituted” is replaced with a selection from the indicated group(s), or with a suitable group known to those of skill in the art, provided that the indicated atom's normal valency is not exceeded and that the substitution results in a stable compound.
  • Suitable indicated groups include, e.g., alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, alkylamino, dialkylamino, trifluoromethylthio, difluoromethyl, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroarylsulfinyl,
  • alkyl refers to a branched, unbranched, or cyclic hydrocarbon having, for example, from 1 to 30 carbon atoms, and often 1 to 12, or 1 to about 6 carbon atoms.
  • Examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-methyl-l- propyl, 2-butyl, 2-methyl-2-propyl (7-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3- methy 1-2 -butyl, 3 -methyl- 1 -butyl, 2-methyl-l -butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2- pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3- dimethy 1-2 -butyl, 3,3-dimethyl-2-butyl, hexyl, octyl, decyl, dodecyl, and the like.
  • the alkyl can be unsubstituted or substituted.
  • the alkyl can also be optionally partially or fully unsaturated. As such, the recitation of an alkyl group includes both alkenyl and alkynyl groups.
  • the alkyl can be a monovalent hydrocarbon radical, as described and exemplified above, or it can be a divalent hydrocarbon radical (i.e., alkylene).
  • alkenyl refers to a monoradical branched or unbranched partially unsaturated hydrocarbon chain (i.e. a carbon-carbon, sp 2 double bond).
  • an alkenyl group can have from 2 to 10 carbon atoms, or 2 to 6 carbon atoms. In other embodiments, the alkenyl group has from 2 to 4 carbon atoms. Examples include, but are not limited to, ethylene or vinyl, allyl, cyclopentenyl, 5-hexenyl, and the like.
  • the alkenyl can be unsubstituted or substituted.
  • alkynyl refers to a monoradical branched or unbranched hydrocarbon chain, having a point of complete unsaturation (i.e. a carbon-carbon, sp triple bond).
  • the alkynyl group can have from 2 to 10 carbon atoms, or 2 to 6 carbon atoms. In other embodiments, the alkynyl group can have from 2 to 4 carbon atoms.
  • This term is exemplified by groups such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1-octynyl, and the like.
  • the alkynyl can be unsubstituted or substituted.
  • cycloalkyl refers to cyclic alkyl groups of from 3 to 10 carbon atoms having a single cyclic ring or multiple condensed rings.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like.
  • the cycloalkyl can be unsubstituted or substituted.
  • the cycloalkyl group can be monovalent or divalent, and can be optionally substituted as described above for alkyl groups.
  • the cycloalkyl group can optionally include one or more cites of unsaturation, for example, the cycloalkyl group can include one or more carbon-carbon double bonds, such as, for example, cyclohexene, 1,3-cyclohexadiene, 1,4- cyclohexadiene, and the like.
  • alkoxy refers to the group alkyl-O-, where alkyl is as defined herein.
  • alkoxy groups include, e.g., methoxy, ethoxy, w-propoxy, z ' so-propoxy, w-butoxy, tert-butoxy, sec-butoxy, w-pentoxy, w-hexoxy, 1 ,2-dimethylbutoxy, and the like.
  • the alkoxy can be unsubstituted or substituted.
  • aryl refers to an aromatic hydrocarbon group derived from the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • the radical can be at a saturated or unsaturated carbon atom of the parent ring system.
  • the aryl group can have from 6 to 30 carbon atoms.
  • the aryl group can have a single ring (e.g., phenyl) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl).
  • Typical aryl groups include, but are not limited to, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like.
  • the aryl can be unsubstituted or optionally substituted, as described above for alkyl groups.
  • halo refers to fluoro, chloro, bromo, and iodo.
  • halogen refers to fluorine, chlorine, bromine, and iodine.
  • haloalkyl refers to alkyl as defined herein substituted by 1 or more halo groups as defined herein, which may be the same or different.
  • the haloalkyl can be substituted with 1, 2, 3, 4, or 5 halo groups.
  • the haloalkyl can by substituted with 1, 2, or 3 halo groups.
  • the term haloalkyl also include perfluoro-alkyl groups.
  • haloalkyl groups include, by way of example, trifluoromethyl, 3-fluorododecyl, 12, 12, 12-trifluorododecyl, 2-bromooctyl, 3-bromo-6- chloroheptyl, ⁇ , ⁇ -perfluorooctyl, and the like.
  • the haloalkyl can be optionally substituted as described above for alkyl groups.
  • heteroaryl is defined herein as a monocyclic, bicyclic, or tricyclic ring system containing one, two, or three aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and that can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, as described above in the definition of "substituted".
  • Typical heteroaryl groups contain 2-20 carbon atoms in addition to the one or more heteroatoms.
  • heteroaryl groups include, but are not limited to, 2H-pyrrolyl, 3H-indolyl, 4H-quinolizinyl, acridinyl, benzo[b]thienyl, benzothiazolyl, ⁇ -carbolinyl, carbazolyl, chromenyl, cinnolinyl, dibenzo[b,d]furanyl, furazanyl, furyl, imidazolyl, imidizolyl, indazolyl, indolisinyl, indolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxazolyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl,
  • heteroaryl denotes a monocyclic aromatic ring containing five or six ring atoms containing carbon and 1, 2, 3, or 4 heteroatoms independently selected from non-peroxide oxygen, sulfur, and N(Z) wherein Z is absent or is H, O, alkyl, aryl, or (Ci-C6)alkylaryl.
  • heteroaryl denotes an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz- derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
  • heterocycle refers to a saturated or partially unsaturated ring system, containing at least one heteroatom selected from the group oxygen, nitrogen, and sulfur, and optionally substituted with one or more groups as defined herein under the term "substituted".
  • a heterocycle can be a monocyclic, bicyclic, or tricyclic group containing one or more heteroatoms.
  • heterocycle groups include 1,3-dihydrobenzofuran, 1,3- dioxolane, 1,4-dioxane, 1,4-dithiane, 2H-pyran, 2-pyrazoline, 4H-pyran, chromanyl,
  • imidazolidinyl imidazolinyl, indolinyl, isochromanyl, isoindolinyl, morpholine, piperazinyl, piperidine, piperidyl, pyrazolidine, pyrazolidinyl, pyrazolinyl, pyrrolidine, pyrroline,
  • heterocycle can include, by way of example and not limitation, a monoradical of the heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. 1960, 82, 5566.
  • “heterocycle” includes a "carbocycle” as defined herein, wherein one or more (e.g. 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (e.g. O, N, or S).
  • heterocycles by way of example and not limitation, include,
  • phenothiazinyl furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatinoyl, and bis- tetrahydrofuranyl.
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • Carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3 -pyridazinyl, 4-pyridazinyl, 5 -pyridazinyl, 6-pyridazinyl, 2- pyrimidinyl, 4-pyrimidinyl, 5 -pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, and the like.
  • nitrogen bonded heterocycles can be bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1- pyrazolyl, and 1 -piperidinyl.
  • carbocycle refers to a saturated, unsaturated or aromatic ring having 3 to 8 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 30 carbon atoms as a polycycle.
  • Monocyclic carbocycles typically have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system.
  • Examples of carbocycles include cyclopropyl, cyclobutyl, cyclopentyl,
  • examples of acyloxy groups include, but are not limited to, acetoxy, propanoyloxy, butanoyloxy, and pentanoyloxy. Any alkyl group as defined above can be used to form an acyloxy group.
  • amino refers to -NH 2 .
  • the amino group can be optionally substituted as defined herein for the term “substituted”.
  • alkylamino refers to -NR 2 , wherein at least one R is alkyl and the second R is alkyl or hydrogen.
  • hydroxyalkyl refers to an alkyl group substituted by -OH.
  • alkylcarboxylic acid refers to an alkyl group substituted by -COOH.
  • amino acid includes a residue of a natural amino acid in D or L form as well as unnatural amino acids (e.g. beta-alanine, phosphoserine, phosphothreonine,
  • phosphotyrosine hydroxyproline, gamma-carboxyglutamate, hippuric acid, octahydroindole-2- carboxylic acid, statine, l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citrulline, alpha-methylalanine, para-benzolylphenylalanine, phenylglycine, propargylglycine, sacrosine, and tert-butylglycine).
  • the term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g. acetyl or
  • benzoylcarboyl as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as (Ci_6 alkyl, phenyl or benzyl ester or amide; or as an alpha-methylbenzyl amide).
  • Other suitable amino and carboxy protecting groups are known to those skilled in the art. (See, e.g., Greene, T.W.; Wutz, P.G.M. Protecting Groups in Organic Synthesis, 2 nd edition, John Wiley & Sons, Inc., New York (1991) and references cited therein).
  • amino acid side chain may also include a side chain containing a known modification such as acetylated, mono-, di- or tri- fluoroacetylated or l-3x methylated lysine, methylated arg (mono, symmetrical bis, asymmetrical bis), phosphorylated Ser, Thr or Tyr, fatty acylation e.g. myristoylation, glycosylation, etc.
  • amino acid side chain refers to any amino acid side chain, whether natural or synthetic, found in an "amino acid” as defined above. This includes, but is not limited to, the twenty standard occurring side chains.
  • peptide refers to a sequence of 2 to 35 amino acids or peptidyl residues.
  • the sequence may be linear or cyclic.
  • a cyclic peptide may result from an appropriate amide or ester linkage or from disulfide formation between two cysteine residues in a sequence.
  • a peptide comprises 3 to 20 or 5 to 15 amino acids.
  • Peptide sequences specifically recited herein are written with the amino terminus on the left and the carboxy terminus on the right.
  • interrupted indicates that another group is inserted between two adjacent carbon atoms (and the hydrogen atoms to which they are attached (e.g., methyl (CH 3 ), methylene (CH 2 ) or methine (CH))) of a particular carbon chain being referred to in the expression using the term "interrupted, provided that each of the indicated atoms' normal valency is not exceeded, and that the interruption results in a stable compound.
  • Alkyl groups can be interrupted by one ore more (e.g., 1, 2, 3, 4, 5, or about 6) of the aforementioned suitable groups. The site of interruption can also be between a carbon atom of an alkyl group and a carbon atom to which the alkyl group is attached.
  • luciferase refers to a naturally occurring, recombinant or mutant luciferase.
  • the luciferase if naturally occurring, may be obtained easily by the skilled person from an organism. If the luciferase is one that occurs naturally or is a recombinant or mutant luciferase, i.e. one which retains activity in a luciferase-luciferin reaction of a naturally occurring luciferase, it can be obtained readily from a culture of bacteria, yeast, mammalian cells, insect cells, plant cells, or the like, transformed to express a nucleic acid encoding the luciferase.
  • the recombinant or mutant luciferase can be derived from an in vitro cell-free system using a nucleic acid encoding the luciferase.
  • Luciferases are available from Promega Corporation, Madison, Wis.
  • bioluminescence or “luminescence” is light produced as a result of a reaction between an enzyme and a substrate that generates light.
  • enzymes include firefly luciferase, e.g. Photinus pyralis or Photinus pennslyvanica, click beetle luciferase, cypridina luciferase, and the like.
  • a "luciferase reaction mixture” contains a luciferase enzyme and materials that will allow the luciferase enzyme to generate a light signal.
  • the materials needed, and the particular concentrations and/or amounts, of the materials needed to generate a luminescent signal will vary depending on the luciferase enzyme used as well as the type of luciferase-based assay being performed.
  • these materials can include: ATP, magnesium (Mg 2+ ) salt, such as magnesium sulfate, a firefly luciferase enzyme, e.g., a thermostable firefly luciferase, and a luciferin capable of generating light when the luciferin is used as a substrate for the firefly luciferase.
  • a buffer to maintain the reaction at the proper pH
  • an additive such as PRIONEX or Bovine serum albumin (BSA) to help maintain luciferase activity
  • reducing agents such as PRIONEX or Bovine serum albumin (BSA)
  • detergents such as PRIONEX or Bovine serum albumin (BSA)
  • BSA Bovine serum albumin
  • An example luciferase reaction mixture would contain a thermostable firefly luciferase, MgS0 4 , ATP, Tergitol NP-9, and Tricine.
  • luciferase reaction mixture would include Oplophorus luciferase, e.g., NanoLuc luciferase, buffer, e.g., Tris-Cl or Tris base, and optionally a background reduction agent, e.g., TCEP.
  • Oplophorus luciferase e.g., NanoLuc luciferase
  • buffer e.g., Tris-Cl or Tris base
  • TCEP background reduction agent
  • the present invention provides a compound according to Formulas (la), (lb) and (Ic):
  • each Y is independently halo, S0 3 H, Ci_ 4 alkyl, substituted Ci_ 4 alkyl, OR 1 or NR X R 2 ; each R 1 is H, Ci_io alkyl or substituted CMO alkyl;
  • each R 2 is H, Ci_io alkyl or substituted CMO alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring
  • n 1 to 6;
  • two Y substituents may join together to form a ring containing from 5 to 7 ring atoms
  • At least one Y is either OH or NR X R 2 .
  • Compounds according to the present invention include, but are not limited to:
  • the invention provides a compound according to Formula (II):
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted Ci R is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (III)
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (IV):
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl;
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (V):
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (VI):
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 1 and R 2 together form a ring.
  • the invention provides a compound according to Formula (VII):
  • each Y is independently OR 1 or NR X R 2 ;
  • each R 1 is independently H, C 1-10 alkyl or substituted C 1-10 alkyl
  • each R 2 is independently H, C 1-10 alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a ring.
  • the emission maximum of the compounds according to the present invention is at least about 650 nm, about 655 nm, about 680, or about 760 nm. nm.
  • the present invention also provides compounds which are substrates for various non- luciferase enzymes and are pro-substrates for luciferase enzymes.
  • the non-luciferase enzymes include, but are not limited to, reductases, glycosidases, proteases, peptidases, oxidases, esterases, cytochrome P450s, beta-lactamases, glycosylases and glutathione transferases.
  • these pro-substrates have a substituent that is a substrate for a non- luciferase position at the one or more Y positions which is cleaved to form
  • each Y is OH or NH 2;
  • n 1 to 3.
  • the compound is a reductase substrate.
  • a reductase substrate has the formula:
  • R is W is S, NR N , or O ;
  • Z is S, NR N , O or CH;
  • RN is H, Ci-4 alkyl, or substituted C 1-4 alkyl.
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • X is CN or Y is OR
  • the compound is a glycosidase substrate.
  • the glycosidase substrate is a compound of formula:
  • A is OR or NHAc
  • each R5 is independently H, a monosaccharide or a polyethylene glycol moiety of up to units.
  • Glycosidase substrates include, but are not limited to, the following compounds:
  • the compound is a protease or protease-dependent protein modifying substrate.
  • the substrate is a compound of formula:
  • R7 is an amino acid side chain
  • R6 is H, a nitrogen protecting group, or a chain of up to 20 amino acids.
  • Suitable nitrogen protecting groups include, but are not limited to, those traditionally known to those skilled in the art, such as Boc, Cbz, Ac and Fmoc.
  • substrates include, but are not limited to, the following compounds:
  • the compound is an oxidase substrate.
  • an oxidase substrate is a compound of formula:
  • X is -CH(OR 10 ) 2 ;
  • Rio is Ci-4 alkyl, substituted C 1-4 alkyl, benzyl, or substituted benzyl;
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • an oxidase substrate is a compound of formula:
  • Y is H or OR
  • R is Ci-io alkyl, substituted C 1-10 alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl.
  • an oxidase substrate is a compound of formula:
  • X is -CH(OR 10 ) 2 ;
  • Rio is Ci-4 alkyl, substituted C 1-4 alkyl, benzyl or substituted benzyl;
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci-io alkyl or substituted C 1-10 alkyl
  • R 2 is H, Ci-io alkyl or substituted C 1-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • Oxidase substrates include, but are not limited to, the following compounds:
  • the compound is a carboxyl-based pro-substrate. In some embodiments, the c
  • R 8 is CH 2 OH, C(0)Rio or -C(0)ZR 9 ;
  • Z is O or H
  • Rg is Ci-7 alkyl or substituted C 1 -7 alkyl
  • Y is OR 1 or NR X R 2 ;
  • R 1 is H, Ci- 10 alkyl or substituted CMO alkyl
  • R 2 is H, Ci-10 alkyl or substituted Ci-10 alkyl; or
  • R 1 and R 2 together form a 4 to 8 membered ring.
  • Carboxyl-based pro-substrates include, but are not limited to, the following compounds:
  • the compound may be a glutathione transferase substrate.
  • each Rii is independently H, Ci_6 alkyl, substituted Ci_6 alkyl, CF 3 , halogen, NO 2 , CO 2 R 12 or any two adjacent Rn can form a fused ring provided that at least one of Rn is O 2 ; and R 12 is H, Ci-6 alkyl or substituted Ci_6 alkyl.
  • Glutathione transferase substrates include, but are not limited to, the following
  • the compound is a beta-lactamase substrate. In some embodim
  • Y is O, NH, N(Ci_7 alkyl), or N(substituted Ci_ 7 alkyl);
  • Z is absent or O
  • A is Ci-4 alkylene or substituted Ci_ 4 alkylene
  • Ri4 is H, phenacetyl, or a cephalosporin side chain.
  • Suitable cephalosporin side chains include those known to one of ordinary skill in the art.
  • Beta-lactamase substrates include, but are not limited to, the following compounds:
  • the present invention also provides compounds which react with various biologically important small molecules, such as hydrogen peroxide, and are pro-substrates for luciferase enzymes. In some embodiments, these compounds are reactive to hydrogen peroxide. In some embodiments, these compounds have the formula:
  • Y is L-R
  • L is a linker
  • R is a boronic acid or borate ester.
  • R is -B(ORis)2 is independently selected
  • R is ; wherein each Ri6 and Ri7 is independently selected from H, C 1-4 alkyl, substituted C 1-4 alkyl, CF 3 , phenyl or substituted phenyl; or R 3 ⁇ 4 and Rn together can be an alkyl ring having from 3-7 carbons or can be replaced by a fused 6-membered aromatic ring.
  • the linker is a direct bond. In other embodiments, the linker is
  • R' is H, Ci-4 alkyl, or substituted C 1-4 alkyl
  • each R 23 is independently halo, H, C 1-4 alkyl, substituted C 1-4 alkyl, C 1-4 hydroxyalkyl, substituted C 1-4 hydroxyalkyl, C 1-4 alkylcarboxylic acid or substituted C 1-4 alkylcarboxylic acid; each R 20 is independently H, halo, CH 3 , OCH 3 , or N0 2 ;
  • each R 2 i is independently H or CH 3 ;
  • n 1 or 2;
  • Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and 1-forms; (+) and (-) forms; keto-, enol-, and enolate- forms; syn- and anti-forms; synclinal- and anticlinal-forms; a- and ⁇ - forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and half-chair forms; and combinations thereof, hereinafter collectively referred to as "isomers” (or "isomeric forms").
  • isomers are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
  • a reference to a methoxy group, -OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH 2 OH.
  • a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta- chlorophenyl.
  • a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C 1-7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and
  • H may be in any isotopic form, including 3 ⁇ 4 2 H (D), and H (T); C may be in any isotopic form, including C, C, and C; O may be in any isotopic form, including 16 0 and 18 0; and the like.
  • a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof.
  • Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallization and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
  • a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below. It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge et al, J. Pharm. Sci., 66: 1-19 (1977).
  • a salt may be formed with a suitable cation.
  • suitable inorganic cations include, but are not limited to, alkali metal ions such as Na and K , alkaline earth cations such as Ca and Mg , and other cations such as Al .
  • Suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R , H2R2 , NHR 3 , NR4 ).
  • suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
  • An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
  • a salt may be formed with a suitable anion.
  • suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
  • Suitable organic anions include, but are not limited to, those derived from the following organic acids: acetic, propionic, succinic, glycolic, stearic, palmitic, lactic, malic, pamoic, tartaric, citric, gluconic, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, aspartic, benzoic, cinnamic, pyruvic, salicyclic, sulfanilic, 2-acetyoxybenzoic, fumaric, phenylsulfonic, toluenesulfonic, methanesulfonic, ethanesulfonic, ethane disulfonic, oxalic, pantothenic, isethionic, valeric, lactobionic, and gluconic.
  • suitable polymeric anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
  • solvate is used herein in the conventional sense to refer to a complex of solute (e.g., active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono- hydrate, a di-hydrate, a tri-hydrate, etc.
  • chemically protected form pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions, that is, are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group).
  • a protected or protecting group also known as a masked or masking group or a blocked or blocking group.
  • the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
  • an amine group may be protected, for example, as an amide or a urethane, for example, as: a methyl amide (-NHCO-CH 3 ); a benzyloxy amide (-NHCO-OCH 2 C 6 H 5 , -NHCbz); as a t-butoxy amide (- NHCO-OC(CH 3 ) 3 , -NH-Boc); a 2-biphenyl-2-propoxy amide (-NHCO-OC(CH 3 )2C 6 H 4 C 6 H5, - NH-Bpoc), as a 9-fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH- Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (- NH-Troc), as an allyloxy amide (-NH-All
  • a carboxylic acid group may be protected as an ester for example, as: an Ci-7 alkyl ester (e.g., a methyl ester; a t-butyl ester); a C1-7 haloalkyl ester (e.g., a C1-7 trihaloalkylester); a triCi-7 alkylsilyl-Ci-7 alkyl ester; or a C5-2 0 aryl-Ci-7 alkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, example.g., as a methyl amide.
  • an Ci-7 alkyl ester e.g., a methyl ester; a t-butyl ester
  • a C1-7 haloalkyl ester e.g., a C1-7 trihaloalkylester
  • a thiol group may be protected as a thioether (-SR), for example, as: a benzyl thioether; or an acetamidomethyl ether
  • a general synthetic route is shown in Scheme 1.
  • the appropriately substituted 2- naphthoic acid can be converted to a 2-naphthylamine by conversion to the acyl azide and subsequent Curtius rearrangement to the 2-naphthylamine.
  • Electrophilic aromatic halogenation installs a halogen substituent preferentially at the 1 -position.
  • Treatment with Appel's salt followed by copper iodide-mediated cyclization affords the 2, 1-naphthothiazole core structure which can then be elaborated to the luciferin substrate by reaction with D-cysteine under mild aqueous conditions.
  • Synthetic chemistry transformations and protecting group methodologies useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser 's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
  • the compounds of the invention may be used in any way that luciferase substrates, e.g., luciferins, have been used.
  • luciferase substrates e.g., luciferins
  • they may be used in a bioluminogenic method which employs an analog of luciferin to detect one or more molecules in a sample, e.g., an enzyme, a cofactor for an enzymatic reaction, an enzyme substrate, an enzyme inhibitor, an enzyme activator, or OH radicals, or one or more conditions, e.g., redox conditions.
  • the sample may include an animal (e.g., a vertebrate), a plant, a fungus, physiological fluid (e.g., blood, plasma, urine, mucous secretions and the like), a cell, a cell lysate, a cell supernatant, or a purified fraction of a cell (e.g., a subcellular fraction).
  • physiological fluid e.g., blood, plasma, urine, mucous secretions and the like
  • a cell e.g., a cell lysate, a cell supernatant, or a purified fraction of a cell (e.g., a subcellular fraction).
  • the presence, amount, spectral distribution, emission kinetics, or specific activity of such a molecule may be detected or quantified.
  • the molecule may be detected or quantified in solution, including multiphasic solutions (e.g., emulsions or suspensions), or on solid supports (e.g., particles, capillaries, or assay vessels
  • a derivative of luciferin can be used as a probe of a specific biochemical activity, e.g., apoptosis and drug metabolism.
  • the luciferin concentration is coupled to a specific enzyme activity by a "pro-luciferin” or "pro-substrate” that can be acted on by the specific enzyme of interest.
  • the pro-luciferin is a molecule that cannot support luminescence directly when combined with luciferase, but can be converted into luciferin through catalytic processing by a specific enzyme of interest.
  • the approach can be used for enzymes such as those used in drug metabolism, e.g., cytochrome P450 enzymes, monoamine oxidase, and glutathione S-transferase; and apoptosis, e.g., caspases.
  • the luciferin derivatives of the present invention can be modified to contain a cleavable group, such as 6'-0-methyl.
  • the 6'0-methyl is cleaved, and the pro-luciferin is converted to luciferin which can be detected with a luciferase.
  • the pro-luciferin can be combined with other components necessary to support luminescence to provide a single reagent and a homogeneous assay. For example, when the reagent is added to a sample, luminescence is generated as pro-luciferin is converted to luciferin.
  • similar assays can be developed for other enzymes, small molecules, or other cellular processes that can be linked to the generation of luciferins from pro-luciferins.
  • the luciferin derivatives of the present invention may be used in assay reagents to detect the presence or activity of non- luminescent enzymes such as cytochrome P450 enzymes, proteases or glycosidases.
  • Assays using luminescent enzymes and their substrates are well known in the art.
  • a luminescent enzyme, a luminescent reaction mixture and a luciferin derivative that is a substrate of the non- luminescent enzyme may be added to a sample suspected of containing the non- luminescent enzyme. If the non- luminescent enzyme is present in the sample, the non-luminescent enzyme will act on the luciferin derivative to derive a substrate recognized by the luminescent enzyme to produce a luminescent signal.
  • the non-luminescent enzyme may convert a luminogenic luciferin derivative to a non- luminescent form, i.e., in a loss of signal assay.
  • the luciferin derivative may be added to the sample prior to or at the same time as the luminescent enzyme.
  • the sample may be a cell.
  • Cells may be eukaryotic cells, e.g., yeast, avian, plant, insect or mammalian cells, including but not limited to human, simian, murine, canine, bovine, equine, feline, ovine, caprine or swine cells, or prokaryotic cells, or cells from two or more different organisms, or cell lysates or supernatants thereof.
  • the cells may have been genetically modified via recombinant techniques.
  • the cell may be in an animal, e.g., transgenic animals, or physiological fluid, e.g., blood, plasma, urine, mucous secretions or the like.
  • the sample may contain more than one non-luminescent enzyme to be detected.
  • more than one luminescent enzyme may be used.
  • more than one substrate may be used. Multiple substrates and/or luminescent enzymes may be used to detect multiple non-luminescent enzymes or other molecule(s) of interest, e.g. test compounds, at the same time, e.g. in a multiplex reaction.
  • the luciferin derivatives are also useful in in situ methods of analyzing cells.
  • luciferin derivatives are not substrates of the luminescent enzymes prior to exposure to a non-luminescent enzyme. However, upon exposure to the non- luminescent enzyme, the derivatives are converted into compounds that can be readily detected in a light-emitting reaction in the presence of a luminescent enzyme. Thus, it may be determined where the non-luminescent enzyme is located in a cell by in situ imaging. This may be done by contacting a cell expressing a luminescent enzyme with a luciferin derivative.
  • a transgenic animal expressing a gene for a luminescent enzyme can be administered a luciferin derivative that is a substrate for a particular non-luminescent enzyme of interest. Imaging technology (e.g. in vivo biophotonic imaging) can then be used to measure luminescence at the site of luminescent enzyme expression in the living, intact animal.
  • a transgenic animal expressing a luminescent enzyme may be administered a luciferin derivative that will be converted into a substrate for the luminescent enzyme in tissues where the appropriate non- luminescent enzyme of interest is expressed. If the luminescent enzyme is also expressed in that tissue, a luminescent signal will be produced and can be detected by any suitable means.
  • test compounds e.g. drugs, can be tested in an animal-based assay. The test compound should be administered to the animal prior to the luciferin derivative.
  • tissue from transgenic animals can be used in tissue based assay.
  • a non-transgenic animal may be administered a luciferin derivative that is a substrate for a particular non- luminescent enzyme of interest.
  • the derivative will be converted into a substrate for a luminescent enzyme in tissues where the appropriate non- luminescent enzyme is expressed.
  • a biological sample e.g., blood, serum, bile, urine, feces, or tissue, can be obtained from the animal and contacted with a luminescent enzyme.
  • the resulting signal can be detectable by any suitable means.
  • test compounds e.g. drugs, can be tested in an animal-based assay. The test compound should be administered to the animal prior to the luciferin derivative.
  • test compounds such as candidate drugs can be screened and evaluated for their activities as, e.g., (1) substrates of a non-luciferase enzyme, (2) regulators, e.g. inhibitors, inducers or activators, of a non-luciferase enzyme, or (3) modifiers of a cellular condition (e.g., viability, increasing reactive oxygen species, or increasing reducing potential).
  • the luciferin derivatives may also be used to distinguish between substrates and inhibitors of a non-luciferase enzyme.
  • the screening may be performed either in vitro or in vivo.
  • reaction mixtures including but not limited to those that inhibit or prevent inactivation of luciferase, or otherwise extend or enhance luminescent signal.
  • the invention also provides kits.
  • the kit may include one or more of the following: luciferin derivative(s) of which one or more are of the present invention, non-luciferase enzyme(s), luciferin-dependent luminescent enzyme(s), and reaction buffer(s).
  • the reaction buffers may be present in individual formulations for the non-luciferase enzyme reactions and the luminescent enzyme reactions or in a single formulation for a single step assay.
  • the kits of the present invention may also contain inhibitors, activators and/or enhancers for a non-luciferase enzyme(s).
  • the kits of the present invention may also contain a positive and/or negative control for the assay.
  • 6-Methoxy-2-naphthylamine 400 mg, 1.6 mmol was suspended in 20 mL of MeCN with 12 mg of NH 4 OAc (0.16 mmol) and stirred in an ice bath.
  • N-Bromosuccinimide (299 mg, 1.68 mmol) was dissolved in 6 mL of dry MeCN and added slowly over 1 hour (h). The reaction was stirred for an additional hour at 0°C, then adsorbed onto Celite, concentrated under reduced pressure and subjected to silica gel chromatography eluting with 0->60% EtOAc in heptanes to yield 300 mg of an orange solid. 7.94 (d, 1 H); 7.55 (d, 1 H); 7.18 (dd, 1 H); 7.09 (d, 1 H); 7.02 (d, 1 H); 4.29 (br s, 2 H); 3.89 (s, 3 H).
  • tert-Butyl (6-aminonaphthalen-2-yl)carbamate tert-Butyl (6- (azidocarbonyl)naphthalen-2-yl)carbamate (2.7 g, 8.64 mmol) in 75 mL of toluene was heated to reflux for 2 h. A 6 M solution (10 mL, 60 mmol) of aqueous NaOH was added, and the reaction was heated at reflux for 72 h. The reaction was cooled to RT and filtered. The filtrate was extracted with 3 x EtOAc, and the combined organic layers dried over Na 2 S0 4 and evaporated to yield 1.62 g of a slightly pink solid.
  • tert-Butyl (6-amino-5-bromonaphthalen-2-yl)carbamate tert-Butyl (6- aminonaphthalen-2-yl)carbamate (1.31 g, 5.07 mmol) was stirred with ammonium acetate (39 mg, 0.5 mmol) in MeCN in an ice bath. N-Bromosuccinimide (948 mg, 5.32 mmol) was dissolved in additional MeCN and added slowly over 1 h. Stirring was continued for 1 h at 0°C, and then Celite was added.
  • tert-Butyl (2-cyanonaphtho[2,l-d]thiazol-7-yl)carbamate To a stirred solution of tert-butyl (6-amino-5-bromonaphthalen-2-yl)carbamate (540 mg, 1.6 mmol) in dry DCM, 351 mg of Appel's salt (1.68 mmol) was added. Upon completion, the reaction was diluted with EtOAc and washed with water. The organic layer was dried over Na 2 S0 4 and evaporated. The crude material thus obtained was dissolved in 10 mL of pyridine and treated with 529 mg (2.78 mmol) of Cul.
  • the reaction was heated in a 110°C oil bath for 40 min, and then the solvents were removed under reduced pressure.
  • the resulting solids were taken up in EtOAc and filtered.
  • the filtrate was washed with 1 N HC1, the aqueous layer extracted with 2 x EtOAc, and the combined organic layers dried over Na 2 S0 4 .
  • the solvents were removed under reduced pressure, and the resulting material subjected to silica gel chromatography eluting with 15->35% EtOAc in heptanes to yield 148 mg of a yellow solid.
  • the reaction was transferred to an ice bath and allowed to stir for 72 h with concomitant warming to RT.
  • the reaction was diluted with DCM and washed with 1 N HC1, the aqueous layer was extracted with 2 x DCM, and the combined organic layers dried over Na 2 S0 4 and adsorbed onto Celite.
  • Silica gel purification eluting with 0->60% EtOAc in heptanes afforded 117 mg of the desired product.
  • a 20uM solution of Leu-luciferin and a 20uM solution of PBI-5044 were prepared in a solution of lOOmM HEPES/0.1% Prionex.
  • the 20uM solution of PBI-5044 was then serially diluted in the HEPES/Prionex solution to 2uM and 0.2uM solutions.
  • lU/ml Leu-aminopeptidase (Sigma) was serially diluted ( Figure 1) into each of the luciferin dilutions (20uM Leu-luciferin, 20uM PBI-5044, 2uM PBI-5044 or 0.2uM PBI-5044). For example, 50ul lU/ml Leu-aminopeptidase was added to 450ul luciferin dilution (final concentration of Leu-aminopeptidase was 0. lU/ml). Leu-aminopeptidase was then serially diluted by adding 150ul Leu-aminopeptidase solution to 350ul of each prepared luciferin derivative.
  • FIG. 1 shows the bioluminescent response of leucine adducts of aminoluciferin control (Leu-luciferin; black circles) or aminoisonaphtholuciferin (PBI-5044; gray squares) as a function of added aminopeptidase.
  • FIG. 2 shows the Km of leucinyl aminoisonaphtholuciferin with respect to aminopeptidase.
  • Aminopeptidase was diluted to O.Olu/ml into a solution containing lOOmM HEPES pH 7.5 and 0.1% Prionex. The following solutions were then prepared in the aminopeptidase dilution:
  • FIG. 3 shows the effects of filters on separating bioluminescence of luciferin from aminoisonaphtholuciferin (PBI-5044).
  • Luminescence was detected on a GloMax® Multi+ luminometer (Promega).
  • FIGS. 4A and 4B show the effects of esterase on PBI-5045.
  • FIG. 4A shows the luminescence (RLUs), and
  • FIG. 4B shows the fold luminescence over background. These results demonstrate an embodiment of a luminescent ester pro-substrate and its successful use in reporting esterase activity.
  • Example 8 Cell Toxicity Studies
  • PBI-4739 or PBI-4813 were prepared at a concentration of 5 mM in DMEM with 10% serum and then two-fold serially diluted in culture medium. The titration series was than added to HeLa monolayers and incubated at 37 °C. At 24 hours, the media containing the substrates was replaced with serum free DMEM and toxicity (ATP) was measured by CellTiter- Glo® Luminescent Cell Viability Assay according to the manufacturer's instructions (Promega Corporation).
  • PBI-4739 or PBI-4813 Three dosages of PBI-4739 or PBI-4813 were administered intraperitoneally as a single dose and compared to 3 dosages of D-luciferin. The animals were monitored for 5 days for clinical findings, behavioral changes and survival. Body weights were monitored daily. Necropsy was performed in the highest does groups for PBI-4739, PBI-4813, D-luciferin and vehicle only (DPBS; Sigma Aldrich). The animals were 40 female, CD-I mice age 6 weeks with a mean body weight of 27.4 + 1.6 [SD].
  • Table 1 lists the dosage groups. Each group contained 4 animals.
  • FIGS. 6-10 provide the data from the clinical signs and animal behavior (FIG. 6), survival rate (FIG. 7), body weights (grams; FIG. 8), body weights (%; FIG. 9) and necropsy results (FIG. 10).
  • ATP was added to a concentration of ImM to Bright-GloTM Luciferase Assay Buffer (Promega Corporation Cat. No. E264A).
  • PBI- 4739 and PBI-4813 (lOOmM DMSO stock) was diluted to 1 : 100 into Bright-GloTM Luciferase Assay buffer (ImM final).
  • 50ul of each substrate was added to 50ul of Click Beetle Red purified enzyme (0.5mg/ml; Promega Corporation) in triplicate and then the samples assayed using a Tecan M-1000 in spectral scan mode using 2nm steps for 4739 and 5nm steps for 4813.
  • FIG. 14 provides the spectral data for the two substrates demonstrating their near-IR properties.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne de nouveaux dérivés de luciférine à émission décalée vers le rouge et des utilisations desdits composés.
EP14714053.7A 2013-03-12 2014-03-07 Luciférines décalés vers le rouge et procédés d'utilisation correspondants Active EP2970246B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777208P 2013-03-12 2013-03-12
PCT/US2014/021678 WO2014159044A1 (fr) 2013-03-12 2014-03-07 Luciférines à émission décalée vers le rouge et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2970246A1 true EP2970246A1 (fr) 2016-01-20
EP2970246B1 EP2970246B1 (fr) 2018-02-21

Family

ID=50391460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14714053.7A Active EP2970246B1 (fr) 2013-03-12 2014-03-07 Luciférines décalés vers le rouge et procédés d'utilisation correspondants

Country Status (4)

Country Link
US (2) US9447450B2 (fr)
EP (1) EP2970246B1 (fr)
JP (2) JP6495232B2 (fr)
WO (1) WO2014159044A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970246B1 (fr) 2013-03-12 2018-02-21 Promega Corporation Luciférines décalés vers le rouge et procédés d'utilisation correspondants
EP3191600A1 (fr) 2014-09-11 2017-07-19 Promega Corporation Substrats émettant dans l'infrarouge utilisant des séquences de luciférase pour produire une luminescence augmentée
EP3548470B1 (fr) 2016-12-01 2023-11-01 Promega Corporation Luciférines à disubstitution en positions 5,5 et leur utilisation dans des dosages à base de luciférase
US11136615B2 (en) 2017-08-04 2021-10-05 Promega Corporation Compositions and methods for stabilizing benzothiazole luciferin analogs
WO2020041579A1 (fr) 2018-08-23 2020-02-27 Promega Corporation Analogues de coelentérazine
KR20230158540A (ko) 2021-03-19 2023-11-20 칸토 덴카 코교 가부시키가이샤 D-루시페린 및 d-루시페린 유도체, 그리고 이들 화합물의 전구체, 그리고 이들의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998204A (en) 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
ATE513838T1 (de) * 2002-09-20 2011-07-15 Promega Corp Auf lumineszenz basierende verfahren und sonden zur messung der cytochrom-p450-aktivität
EP1935986B1 (fr) 2005-05-31 2014-04-16 Promega Corporation Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
EP2778234B1 (fr) * 2005-05-31 2017-09-27 Promega Corporation Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
WO2008109459A1 (fr) 2007-03-02 2008-09-12 University Of Massachusetts Luciférines
EP2222870B1 (fr) * 2007-10-29 2012-06-27 PerkinElmer Health Sciences B.V. Procédés, réactifs et trousses de dosage de luciférase
JP5464311B2 (ja) 2008-02-02 2014-04-09 国立大学法人電気通信大学 ルシフェラーゼの発光基質
US8288559B2 (en) 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
EP2744521B1 (fr) * 2011-08-16 2017-04-05 Promega Corporation Détection de peroxyde d'hydrogène
EP2970246B1 (fr) 2013-03-12 2018-02-21 Promega Corporation Luciférines décalés vers le rouge et procédés d'utilisation correspondants

Also Published As

Publication number Publication date
EP2970246B1 (fr) 2018-02-21
US9868977B2 (en) 2018-01-16
US20170002396A1 (en) 2017-01-05
US9447450B2 (en) 2016-09-20
JP6724119B2 (ja) 2020-07-15
JP6495232B2 (ja) 2019-04-03
JP2019068817A (ja) 2019-05-09
JP2016521291A (ja) 2016-07-21
US20140304842A1 (en) 2014-10-09
WO2014159044A1 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
JP6724119B2 (ja) 赤方偏移ルシフェリン及びその使用方法
EP2272973B1 (fr) Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
US20140093894A1 (en) Compounds and methods for assaying redox state of metabolically active cells and methods for measuring nad(p)/nad(p)h
US8288559B2 (en) Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
EP2611929B1 (fr) Dosage de glutathion oxydé
EP3181151B1 (fr) Détection de péroxyde d'hydrogène
EP2545041B1 (fr) Dosages bioluminescents faisant appel à des composés de cyanobenzothiazole
EP2331517B1 (fr) Dosages bioluminescents au moyen de composés cyanobenzothiazole
EP1935986A2 (fr) Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
US10280447B2 (en) Substituted imidazo[1,2-A]pyrazines tethered to energy acceptors
EP3981839A1 (fr) Analogues de la coelentérazine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161020

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170905

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 971576

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014021183

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180221

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 971576

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180521

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180521

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180522

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014021183

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180331

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180307

26N No opposition filed

Effective date: 20181122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140307

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180621

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240327

Year of fee payment: 11

Ref country code: GB

Payment date: 20240327

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240325

Year of fee payment: 11